Publications

Publications

Filter Results: (9) Arrow Down

Show Results For

Page 1 of 9 Results
Sort by

Are you looking for?

→Search All HBS Web
  • January 2018
  • Article

Innovation Incentives and Biomarkers

By: Ariel Dora Stern, Brian M. Alexander and Amitabh Chandra
Previously, we have discussed the importance of economic incentives in shaping markets for precision medicines. Here we consider incentives for biomarker development, including discovery and establishment. Biomarkers can reveal valuable information regarding diagnosis... View Details
Keywords: Health Care and Treatment; Innovation and Invention; Research and Development; Markets
Related
  • Article

Managing the Use and Dissemination of Information about Biomarkers: The Importance of Incentive Structures.

By: Ariel Dora Stern
The use of biomarkers holds great promise for the development of new therapeutics and the acceleration of clinical research. However, biomarkers must be validated—a complex and costly endeavor. Importantly, biomarker validation is meaningfully shaped by economic and... View Details
Keywords: Biomarkers; Information Management; Health Care and Treatment; Motivation and Incentives
Related
  • 11 Apr 2017
  • First Look

First Look at New Research, April 11

Alexander, and Amitabh Chandra Abstract—Many public and private efforts in coming years will focus on research in precision medicine, developing biomarkers to indicate which patients are likely to benefit from a certain treatment so that... View Details
  • March 17, 2017
  • Article

How Economics Can Shape Precision Medicines

By: Ariel Dora Stern, Brian M. Alexander and Amitabh Chandra
Many public and private efforts in coming years will focus on research in precision medicine, developing biomarkers to indicate which patients are likely to benefit from a certain treatment so that others can be spared the cost—financial and physical—of being treated... View Details
Keywords: Health Care and Treatment; Research; Economics; Motivation and Incentives
Related
  • March 2021
  • Article

Provider Teams Outperform Solo Providers in Managing Chronic Diseases and Could Improve the Value of Care

By: Maximilian J. Pany, Lucy Chen, Bethany Sheridan and Robert S. Huckman
Scope-of-practice regulations, including prescribing limits and supervision requirements, may influence the propensity of providers to form care teams. Therefore, policy makers need to understand the effect of both team-based care and provider type on clinical... View Details
Keywords: Disease Management; Team-based Care; Health Care and Treatment; Groups and Teams; Performance
Related
  • 2018
  • Chapter

The Orphan Drug Act at 35: Observations and an Outlook for the Twenty-First Century

By: Nicholas Bagley, Benjamin Berger, Amitabh Chandra, Craig Garthwaite and Ariel Dora Stern
On the 35th anniversary of the adoption of the Orphan Drug Act (ODA), we describe the enormous changes in the markets for therapies for rare diseases that have emerged over recent decades. The most prominent example is the fact that the profit-maximizing price of new... View Details
Keywords: Health Care and Treatment; Laws and Statutes; Research and Development; Investment; Markets; Monopoly
Related
  • 31 Oct 2017
  • First Look

New Research and Ideas, October 31, 2017

Potential of Patient-Reported Outcomes By: Rotenstein, Lisa, Robert S. Huckman, and Neil Wagle Abstract—No abstract available. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=53372 forthcoming Clinical Pharmacology & Therapeutics Innovation... View Details
Keywords: by Sean Silverthorne
  • 05 Nov 2014
  • What Do You Think?

Are We Entering an Era of Neuromanagement?

participants with higher gray matter volume in this region exhibited less risk aversion. The results "identify what might be considered the first stable biomarker for financial risk-attitude," according to the authors. The study... View Details
Keywords: by James Heskett
  • 18 Dec 2018
  • First Look

New Research and Ideas, December 18, 2018

firms face little competition, even after the end of formal periods of patent protection and market exclusivity. Additionally, the evolving technologies of drug development—in particular, the increasingly common use of auxiliary endpoints in clinical trials and the use... View Details
Keywords: Dina Gerdeman

Are you looking for?

→Search All HBS Web